Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study by Agarwal, Sunil K. et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Airflow obstruction, lung function, and risk
of incident heart failure: the Atherosclerosis
Risk in Communities (ARIC) study
Sunil K. Agarwal1*, Gerardo Heiss1, R. Graham Barr2, Patricia P. Chang1,
Laura R. Loehr1, Lloyd E. Chambless1, Eyal Shahar3, Dalane W. Kitzman4,
and Wayne D. Rosamond1
1University of North Carolina, Chapel Hill, NC, USA; 2Columbia University Medical Center, New York, NY, USA; 3University of Arizona, Tucson, AZ, USA; and 4Wake Forest
University School of Medicine, Winston-Salem, NC, USA
Received 4 November 2011; revised 20 December 2011; accepted 13 January 2012; online publish-ahead-of-print 25 February 2012
See page 348 for the editorial comment on this article (doi:10.1093/eurjhf/hfs022)
Aims We examined the relationship between forced expiratory volume in 1 s (FEV1), airflow obstruction, and incident
heart failure (HF) in black and white, middle-aged men and women in four US communities.
Methods
and results
Lung volumes by standardized spirometry and information on covariates were collected on 15 792 Atherosclerosis
Risk in Communities (ARIC) cohort participants in 1987–89. Incident HF was ascertained from hospital records and
death certificates up to 2005 in 13 660 eligible participants. Over an average follow-up of 14.9 years, 1369 (10%)
participants developed new-onset HF. The age- and height-adjusted hazard ratios (HRs) for HF increased monoton-
ically over descending quartiles of FEV1 for both genders, race groups, and smoking status. After multivariable adjust-
ment for traditional cardiovascular risk factors and height, the HRs [95% confidence intervals (CIs)] of HF comparing
the lowest with the highest quartile of FEV1 were 3.91 (2.40–6.35) for white women, 3.03 (2.12–4.33) for white men,
2.11 (1.33–3.34) for black women, and 2.23 (1.37–3.59) for black men. The association weakened but remained stat-
istically significant after additional adjustment for systemic markers of inflammation. The multivariable adjusted inci-
dence of HF was higher in those with FEV1/forced vital capacity ,70% vs. ≥70%: HR 1.44 (95% CI 1.20–1.74) among
men and 1.40 (1.13–1.72) among women. A consistent and positive association with HF was seen for self-reported
diagnosis of emphysema and chronic obstructive pulmonary disease, but not for asthma.
Conclusions In this large population-based cohort with long-term follow-up, low FEV1 and an obstructive respiratory disease were
strongly and independently associated with the risk of incident HF.
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Introduction
Heart failure (HF) is a major cause of disability and premature mor-
tality.1 It has a poor prognosis, and the costs associated with its
treatment exceed those for coronary artery disease and cancer
combined.1 Chronic obstructive pulmonary disease (COPD)
remains one of the leading causes of morbidity and mortality in
the developed world2.
Chronic obstructive pulmonary disease is a common co-
morbidity among patients with HF, and vice versa.3 A large body
of literature suggests that higher cardiovascular mortality occurs
in individuals with COPD and low lung volumes.2,4 A connection
between HF and COPD has been alluded to in the literature. In
patients with COPD, the predicted percentage of forced expira-
tory volume in 1 s (FEV1) was inversely associated with left ven-
tricular ejection fraction,5 and cor pulmonale in particular is a
* Corresponding author. Department of Epidemiology, University of North Carolina, 137 E. Franklin Street, Suite 32, Chapel Hill, NC 27514, USA. Tel: +1 919 265 4727,
Fax: +1 919 966 9800, Email: sunilagarwal@unc.edu
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com.
European Journal of Heart Failure (2012) 14, 414–422
doi:10.1093/eurjhf/hfs016
well-recognized complication of severe COPD; further, severe
COPD is associated with impaired left ventricular filling.5,6 Recently
published studies suggest that left ventricular diastolic and systolic
dysfunction are frequently seen in mild and even subclinical
COPD7 and emphysema.8 However, only a few recently published
studies have reported an association between subclinical or
spirometry-based airflow obstruction and incident HF in
middle-aged men,9 in healthy older adults,10 and in those with
either systolic or diastolic dysfunction at baseline.11
To our knowledge, there are limited population-based reports
that systematically examine the relationship between COPD
(spirometry-based airflow obstruction, clinical definition, and self-
reported diagnosis) and the risk of incident HF. We hypothesized
that low FEV1 as well as airflow obstruction in individuals without
HF is associated with increased risk of subsequent HF, and that this
relationship would be consistent across groups defined by race,
gender, and smoking status. We addressed these questions in a
large biracial cohort of middle aged men and women sampled
from four US communities.
Methods
Study population
The Atherosclerosis Risk in Communities (ARIC) study enrolled 15
792 men and women aged 45–64 years sampled from four US com-
munities: Forsyth County, NC; Jackson, MS; seven north-western
suburbs of Minneapolis, MN; and Washington County, MD. Enrolment
at the Jackson, MS site was restricted to black residents, while black
residents were oversampled in Forsyth County. The ARIC study
protocol was approved by the institutional review board of each par-
ticipating university, and written informed consent was obtained from
study participants at the baseline visit. Baseline examinations of the
cohort were conducted from 1987 to 1989 to collect standardized in-
formation on socioeconomic indicators, medical history, family history,
cardiovascular risk factors, serum chemistries, electrocardiograms
(ECGs), medication use, and lung volumes. Three re-examinations fol-
lowed the baseline visit, as well as annual telephone interviews and
active surveillance of hospitalizations and death.
Those with prevalent HF (n ¼ 775) or missing (n ¼ 325) data on HF
at baseline, missing (n ¼ 127) or implausible (n ¼ 12) lung volume data,
missing information on important covariates (n ¼ 780), and race other
than black or white (n ¼ 48) were excluded from these analyses. The
final study sample was 13 660.
Exposure
Pulmonary function was assessed at the baseline visit (1987–89) using a
water-sealed Collins Survey II volume displacement spirometer (Collins
Medical, Inc.) and Pulmo-Screen II software (PDS Healthcare Products,
496 Inc.). Spirometry was conducted using American Thoracic Society
(ATS) guidelines.12 From at least three acceptable readings, of which at
least two were reproducible (volumes within +5%), a best reading was
selected by computer software and confirmed by a technician using
ATS criteria for acceptability. The protocol was standardized across
the four field centres, with training and certification of pulmonary tech-
nicians and extensive quality assurance throughout the study.
History of respiratory disease was obtained via a standardized ques-
tionnaire by trained personnel.13 Participants were also asked whether
they were ever diagnosed with bronchitis/emphysema/asthma, and
whether these were confirmed by a doctor. Chronic bronchitis was
defined as productive cough for at least 3 months in two contiguous
years. COPD was defined by a positive response to a physician diagno-
sis of either emphysema or chronic bronchitis. Post-bronchodilator
measurements are required to define COPD optimally per GOLD
classification,2 but only pre-bronchodilator measurements were avail-
able in this study. An FEV1/forced vital capacity (FVC) ratio of ,0.7
was also used to define airflow obstruction. Those with airflow ob-
struction were further divided into mild (FEV1 ≥80% of predicted
value) and moderate/severe (FEV1 ,80% of predicted).
2
Covariates
At baseline, prevalent coronary heart disease (CHD) was ascertained
by self-report and a 12-lead ECG. Hypertension was defined by dia-
stolic pressure ≥90 mmHg or systolic pressure ≥140 mmHg on the
average of the last two of three measurements, or the use of antihy-
pertensive medications. Diabetes was defined by the presence of a
serum glucose level ≥200 mg/dL, an 8 h fasting glucose level
≥126 mg/dL, a self-reported history of physician-diagnosed diabetes,
or the current use of hypo-/antihyperglycaemic medications. Heart
rate was derived from the 12-lead ECG. Medication intake including
beta-blockers was self-reported or coded from medicines brought
by participants during the exam. Cigarette smoking status was
defined as currently smoking, or a history of ever smoking ≥400 cigar-
ettes. The average number of cigarettes/day and number of years of
smoking reported were multiplied to derive cigarette-years of
smoking. Body mass index was defined as the ratio of measured
weight (kg) and measured height2 (in m2). Participants identified them-
selves as American/Alaskan Indian, Asian, black, or white race.
Heart failure
Incident HF was defined as the first HF hospitalization with an HF dis-
charge code or HF as the underlying cause of death on a death certifi-
cate (n ¼ 84). Hospital discharge diagnoses were coded using the
International Classification of Diseases Code, Ninth Revision (ICD-9,
code 428), and deaths were coded using ICD-9 or ICD-10 (codes
428 and I 50, respectively). Cohort follow-up for the current analysis
ended on 31 December 2004.
Statistical methods
Means (standard deviations) and proportions of characteristics at base-
line and follow-up HF event rates were calculated for quartiles of FEV1.
A higher proportion of blacks and women were in the lower quartiles
of FEV1 and FVC; thus all analyses (except for Table 1) used race- and
gender-specific quartiles of FEV1. Incidence density (rate) of HF in
various strata was estimated assuming a Poisson distribution. Cox re-
gression models were used to assess the relationship between race-
and gender-specific quartiles of FEV1 (and FVC), and airflow obstruc-
tion with incident HF for each race and gender group.
All Cox models were adjusted for age, height, and squared height
(height2), since use of percentage predicted lung function(s) can
violate the assumptions of homogeneity of variance required to inter-
pret the estimates correctly and has been discouraged, in favour of ad-
justment using height2 and height.14 The potentially strong confounding
due to cigarette smoking was addressed by stratified analysis by
smoking for each race and gender group. Further, models were
adjusted for prevalent CHD and its traditional risk factors. As
chronic inflammation may act as both a confounder and an intermedi-
ary for this association, a change in the magnitude of the estimates after
additional adjustment for pro-inflammatory, pro-coagulability markers
and obesity was evaluated with an understanding that either of the esti-
mates may be biased and it requires multiple values of both exposure
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and confounder/intermediary to be able to adjust for only the con-
founding effect and not more. Statistical adjustment for an intervening
variable or effect may result in bias towards the null; conversely,
residual confounding may result in bias away from the null.15 Lastly, ad-
justment for maximum inspiratory pressure was done to adjust for
overall decreased muscle strength.
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Table 1 Characteristics of study participants at baseline and incident heart failure across quartiles of forced expiratory
volume in 1 s (n 5 13 360)
FEV1 quartile at baseline
a









Age (in years) 56.06 (5.6) 54.15 (5.7) 53.45 (5.7) 52.62 (5.4)
Male 14.6 21.5 51.2 93.3
African American 39.1 27.2 20.6 11.6
Hypertension 41.8 31.7 29.7 23.5
Diabetes 15.1 9.6 9.4 7.4
Current smoker 36.5 25.3 21.6 17.7
Former smoker 21.3 26.6 34.7 44.8
Cigarette-years of smoking 361.6 (467.9) 269 (397.5) 305.6 (434.5) 307.9 (386.3)
Usual ethanol intake (g/week) 27.9 (82.3) 31.2 (75.6) 49.1 (107.1) 62.6 (106.3)
Height (cm) 161.9(7.5) 164.8 (7.1) 169.9 (7.3) 177.6 (6.5)
Systolic blood pressure (mmHg) 124.9 (20.4) 120.1 (18.4) 119.4 (18.1) 118.4 (15.6)
Diastolic blood pressure (mmHg) 73.2 (11.8) 72.6 (10.9) 73.5 (11.0) 74.4 (10.3)
LDL-cholesterol (mg/dL) 139.4 (42.0) 136.2 (38.4) 136.3 (38.8) 138.2 (36.6)
HDL-cholesterol (mg/dL) 55.4 (17.7) 55.4 (16.9) 52.2 (17.4) 45.5 (13.8)
Body mass index (kg/m2) 28.2 (6.4) 27.4 (5.5) 27.1 (4.9) 27.2 (3.7)
Inflammatory markers
White blood count (×103/mm3) 6.4 (2.1) 6 (1.9) 6 (1.8) 5.9 (2.1)
Fibrinogen (mg/dL) 322.4 (71.0) 302 (61.3) 297 (61.6) 284.5 (55.9)
Albumin (g/dL) 3.2 (0.7) 3.2 (0.6) 3.1 (0.6) 3.1 (0.6)
von Willebrand’s factor (%) 126.1 (53.2) 117.1 (46.6) 114.1 (44.2) 110 (42.6)
Study exposure (S)
FEV1 (L) 1.9 (0.3) 2.5 (0.1) 3 (0.2) 3.9 (0.4)
FVC (L) 2.8 (0.5) 3.4 (0.4) 4 (0.4) 5.1 (0.6)
FEV1/FVC 70.8 (11.0) 75.1 (6.8) 75.6 (6.4) 76.3 (5.4)
FEV1/FVC ,70% 41.1 22.5 20.6 15.8
Chronic bronchitisc 7.6 4.1 4.3 3.8
Self-reported diagnosis of
bronchitis
13.3 6.9 5.3 3.7
Self-reported diagnosis of
emphysema
3.7 0.9 0.8 0.7
Self-reported diagnosis of COPDd 15.4 7.5 5.9 4.3
Self-reported diagnosis of asthma 8.5 4.3 4.2 3.5
Follow-up
Heart failure events 16.2 9.3 8.3 6.3
Follow-up duration (in years) 14 (4.3) 15.1 (3.4) 15.1 (3.3) 15.4 (3.0)
Heart failure rate/1000 person
years
11.5 6.1 5.5 4.1
Data are from the Atherosclerosis Risk in Communities (ARIC) study baseline examination (1987–89) in a subsample without prevalent HF and not missing information on
important covariates, followed up to 31 December 2004.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
aForced expiratory volume in 1 s measured using standardized spirometry at study baseline.
bExpressed as mean and standard deviation (SD) or percentages.
cChronic bronchitis was defined as productive cough for at least 3 months in two contiguous years.
dSelf-reported diagnosis of COPD is the presence of self-reported diagnosis of either bronchitis or emphysema.
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Multivariable adjusted cumulative failure estimates were plotted by
quartiles of FEV1, as the inverse of the survival function [1 – S (t +
0)], to yield the estimated cumulative proportion of those who devel-
oped heart failure at any time point t. To evaluate the potential influ-
ence of a misdiagnosis of incident HF on studied association, additional
sensitivity analyses were carried out (i) by excluding those with base-
line COPD, CHD, or both; and (ii) by censoring HF events with a con-
comitant discharge code for acute exacerbation of COPD, respiratory
failure, or both. Results of the sensitivity analysis are reported in Sup-
plementary material online, Table S1. Compliance with the proportion-
al hazards assumption was examined for the main exposure using log–
log curves, and no obvious violation was seen for FEV1 or FVC quar-
tiles. SAS, version-9.1 and STATA-IC, version-10 software were used
for analysis. A P , 0.05 for a two-sided test was considered statistically
significant.
Results
The 25th, 50th, and 75th percentiles of FEV1 in litres were 1.9, 2.2,
and 2.5 in black females, 2.6, 3.0, and 3.4 in black males, 2.2, 2.5,
and 2.8 in white females, and 3.0, 3.5, and 3.9 in white males. Char-
acteristics of all study participants by decreasing gender-specific
quartiles of FEV1 are shown in Table 1. At study baseline, those
in the lower quartiles of FEV1 had a higher mean age, cigarette-
years of smoking, systolic blood pressure, and markers of inflam-
mation, a lower height, and a higher proportion were current
smokers, black, women, or had some respiratory disease.
During an average follow-up of 14.9 years, incident HF was seen
in 1369 (10%) of the study participants. A monotonic increase in
the rate of incident HF with decreasing quartiles of FEV1 was
seen in both blacks and whites, after adjusting for age and height
(Figure 1). The age- and height-adjusted average incidence rates
of HF per 1000 person years by quartiles of FEV1 (from the
lowest to the highest quartile) were 14.7, 8.2, 5.1, and 2.9 for
blacks, and 11.8, 6.6, 4.1, and 2.3 for whites.
Forced expiratory volume in 1 s and
incident heart failure
In Cox regression models adjusted for age, smoking, and height,
the hazard ratios (HRs) of HF increased monotonically and in-
versely by quartiles of FEV1, for both genders in each race group
(Figure 2). The age- and height-adjusted HRs and their 95% confi-
dence interval (95% CIs) comparing those in the lowest quartile of
FEV1 with those in the highest for HF were 3.48 (2.24–5.40)
among black female, 2.88 (1.80–4.61) among black males, 6.95
(4.42–10.94) among white female, and 5.66 (4.04–7.91) among
white males. The HRs comparing the highest with the lowest quar-
tile were of greater magnitude in whites than in blacks, and in
women than in men, and were statistically significant for all com-
parisons with the highest quartile except for the third quartile
among black males. In similar models, HR estimates when compar-
ing quartiles of FVC were slightly higher than for FEV1 (data not
shown).
The above associations were observed across all smoking status
categories. In analyses restricted to the never smokers group, the
age-, height-, and height2-adjusted HF estimate of the HR was
2.5–3 times higher in the lowest quartile of FEV1 than in the
highest (Table 2).
In multivariable models adjusted for age, height, prevalent CHD,
and traditional cardiovascular risk factors (model 2), the HRs (95%
CI) comparing the lowest with the highest quartiles of FEV1 were
2.91 (2.14–3.97) for women and 2.23 (1.69–2.93) for men
(Table 2). On further adjustment for covariates including prevalent
Figure 1 Estimated rate of new-onset heart failure (HF) per
1000 person years among black and white cohort members
during an average study follow-up of 14.9 years by gender- and
race-specific quartiles of forced expiratory volume in 1 s
(FEV1). The estimated rates are adjusted for age, height, and
height × height. The estimated rates shown are for an individual
55 years of age, and 5.5 feet in height. Data are from the Athero-
sclerosis Risk in Communities (ARIC) study baseline examination
(1987–89) in a subsample without prevalent HF and not missing
information on important covariates, followed up to 31 Decem-
ber 2004. p-y, person years.
Figure 2 Estimated hazard ratio [95% confidence intervals
(CI)] of incident heart failure for the quartiles of forced expira-
tory volume in 1 s (FEV1) for each gender and race, adjusted
for age, smoking, height, and height × height. The y-axis is
plotted on a log scale with base 2. Data are from the Atheroscler-
osis Risk in Communities (ARIC) study baseline examination
(1987–89) in a subsample without prevalent HF and not
missing information on important covariates, followed up to
31 December 2004.
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CHD and traditional cardiovascular risk factors, body mass index,
white blood cell count, fibrinogen, von Willebrand’s factor, and
serum albumin (model 3) or heart rate, the magnitude of the
HRs was attenuated slightly, although they remained statistically
significant for all race and gender group (Table 2).
The multivariable adjusted cumulative risk of incident HF by
quartiles of FEV1 is shown in Figure 3. A graded increase in the
risk of HF for decreasing quartiles of FEV1 is seen throughout
the study period.
Airflow obstruction and incident heart
failure
In multivariable adjusted models, the HRs for HF comparing those
with FEV1/FVC ,70% with those with FEV1/FVC ≥70% were 1.44
(1.20–1.74) and 1.40 (1.13–1.72) for women and men, respective-
ly (Table 3). Of note, moderately severe airflow obstruction as
defined by spirometry was associated with incident HF but not
mild airflow obstruction. Self-reported COPD was similar to
spirometry-defined COPD in its association with incident HF.
For example, the HR (95% CI) comparing those with a self-
reported diagnosis of COPD with those without was 1.84
(1.47–2.31) for women and 1.44 (1.08–1.91) for men.
On testing the associations of several definitions of respiratory
disease with incident HF, a self-reported physician diagnosis of em-
physema had the strongest association with incident HF in both
men and women, whereas self-reported physician diagnosis of
asthma had a weak association in women, and no association in
men (Table 3).
Discussion
We observed a strong inverse association between baseline lung
function and incident HF, and a monotonic, direct association
between airflow obstruction and incident HF. These associations
were seen across groups defined by race, gender, and smoking
status. Notably, the relationship was also seen in never smokers
and persisted after adjustment for smoking status and cigarette-
years of smoking, indicating that our results are not primarily con-
founded by smoking.
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Table 2 Hazard ratios of heart failure contrasting the lowest and highest quartiles of forced expiratory volume in 1 s by
incremental level of covariate adjustments (N 5 13 360)
Gender Smoking status/
model
White participants (N 5 10 293,
n 5 927)
Black participants (N 5 3367,
n 5 442)
All participants (N 5 13 360,
n 5 1369)
HR (95% CI) HR (95% CI) HR (95% CI)
Women Currenta 9.87 (3.01–32.34) 3.56 (1.50–8.49) 4.94 (2.50–9.76)
Formera 4.35 (1.65–11.50) 2.99 (1.13–7.80) 4.27 (2.13–8.53)
Noa 3.88 (2.03–7.42) 3.01 (1.63–5.56) 4.01 (2.57–6.27)
Model 1b 4.80 (3.00–7.68) 2.98 (1.91–4.66) 4.12 (2.98–5.70)
Model 2c 3.91 (2.40–6.35) 2.11 (1.33–3.34) 2.91 (2.14–3.97)
Model 3d 3.61 (2.21–5.88) 2.00 (1.25–3.19) 2.44 (1.79–3.34)
Model 4e 3.44 (2.03–5.83) 1.61 (0.95–2.72) 2.19 (1.54–3.12)
Men Currenta 2.51 (1.31,–4.81) 2.71 (1.25–5.88) 2.42 (1.48–3.97)
Formera 6.72 (4.07–11.08) 2.91 (1.23–6.88) 5.60 (3.65–8.60)
Noa 3.04 (1.46–6.31) 2.44 (0.94–6.33) 2.94 (1.65–5.22)
Model 1b 4.11 (2.89–5.84) 2.55 (1.57–4.13) 3.51 (2.65–4.66)
Model 2c 3.03 (2.12–4.33) 2.23 (1.37–3.59) 2.23 (1.69–2.93)
Model 3d 2.98 (2.07–4.28) 2.11 (1.30–2.41) 1.92 (1.44–2.55)
Model 4e 2.68 (1.83–3.92) 1.72 (0.96–3.07) 1.80 (1.32–2.44)
Data are from the Atherosclerosis Risk in Communities (ARIC) study baseline examination (1987–89) in a subsample without prevalent HF and not missing information on
important covariates, followed up to 31 December 2004.
FEV1 quartiles were race and gender specific, and the models contained quartiles as indicator variables to estimate the effect size without assuming log-linearity in FEV1 quartiles.
Estimates are reported only contrasting the lowest with the highest quartile of FEV1.
N, study sample size; n, incident heart failure cases; FEV1, forced expiratory volume in 1 s.
Each of the hazard ratios (HRs) and their 95% confidence interval (95% CIs) is from a separate model. For smoking categories, subset analysis was done by running separate models
for each smoking stratum for each race and gender.
aHRs and 95% CI, adjusted for age, height × height2.
Further models with adjustment for incremental level of covariates were:
bModel 1: in addition to age, height, and height × height, this model additionally adjusts for current smoking status by using two binary variables: current smoking and former
smoking, and cigarette-years of smoking.
cModel 2: in addition to model 1 covariates, this model adjusts for prevalent coronary heart disease, diabetes, hypertension, LDL-cholesterol, and HDL-cholesterol.
dModel 3: in addition to model 2 covariates, this model adjusts for fibrinogen levels, white blood count, von Willebrand’s factor, serum albumin, and body mass index.
eModel 4: in addition to model 3, this model adjusts for maximum inspiratory pressure measured during visit 2 (3 years after baseline visit), with fewer observations (whites
n ¼ 9027, blacks n ¼ 2820).
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Low forced expiratory volume in 1 s and
incident heart failure
These results in a population-based cohort are consistent with
clinical observations, but also with four previous reports from
population-based cohorts, indicating that a low FEV1 was strongly
predictive of HF, independent of many traditional and non-
traditional risk markers.9 –11,16 A recently published study reported
an 25% increased risk of HF per standard decrease in FEV1 or
FVC; however, the strength of the association was much lower
when comparing quartile 1 with quartile 4 of FEV1, suggesting
that CHD may be the primary driver of this association in this
cohort of younger men. Similarly, among older adults who were
relatively healthy, a strong association of 21% higher odds per
10% decrease in predicted FEV1 was reported.
10 The present
study extends these results by the length and completeness of
its follow-up, with replication in African Americans, women, and
never smokers.
Airflow obstruction and incident heart
failure
We also found a consistent association of incident HF with
interviewer-ascertained chronic bronchitis, self-reported COPD,
self-reported emphysema, and spirometry-defined airflow obstruc-
tion (FEV1/FVC ,70%), but not with self-reported asthma. Our
results are similar to those of a large retrospective case–control
study based on claims data, where COPD was associated with
an almost three-fold higher rate of HF hospitalization,17 although
the magnitude of the reported association was considerably
bigger than seen in our study. Although no association was seen
between low FEV1/FVC (,60% vs. higher) and HF in the original
Framingham cohort,18 perhaps owing to low power, recent
studies have reported associations of a magnitude similar to the
present study despite many differences in the age, gender, race,
and co-morbidities between the cohorts, as well as different defi-
nitions of airflow obstruction.9 –11
Potential confounders/intermediaries
The associations quantified as HRs were of greater magnitude in
women and in whites than in men and African Americans, respect-
ively. The lower absolute risk of HF in women and in whites is one
explanation (thus similar risk differences), as well as a likely higher
frequency of diastolic HF in these groups than in African
Americans.
Several traditional cardiovascular risk factors are associated with
both low lung function and HF, and thus could confound the asso-
ciations reported here. Both FVC and FEV1 have been shown to
have an inverse association with blood glucose levels, blood pres-
sure, serum cholesterol, body mass index, and left ventricular
mass.19,20 Our estimates were somewhat attenuated after adjust-
ment for these putative confounding variables, but they remained
statistically significant (Tables 2 and 3). Kannel et al. suggested
that decreased muscle strength may partially account for the
inverse association of FEV1 with HF.
18 Statistical adjustment for
maximum inspiratory pressure, a measure of respiratory muscle
strength, indeed attenuated the magnitude of our results.
It has been proposed that lower lung volumes may be seen in HF
patients with large heart size due to lung impingement.21 This is un-
likely to be common in a population sample of middle-aged indivi-
duals without HF at study baseline; moreover, statistical adjustment
for left ventricular mass estimated by the Cornell voltage did not
change the magnitude of our estimates. Overweight and obesity
were also considered as possible confounders. However, no
clear patterns of association between ponderosity and lung func-
tion or respiratory disease were seen in these data, and statistical
adjustment for body mass index did not change our results
appreciably.
Levels of systemic markers of inflammation are higher in those
with low lung volumes, and links between inflammation and HF
have been proposed. These high levels may reflect either a spill
of inflammatory markers from inflammation localized to the
lungs or an upstream up-regulation of the inflammatory
cascade.22 We observed some attenuation of the HR estimates
in our study after adjustment for baseline levels of inflammatory/
haemostatic markers, which lends some support to the
inflammation–HF hypothesis. However, it is far from established
whether inflammation increases the risk of HF beyond its associ-
ation with CHD. Exercise training appears to improve physical
function in both COPD and HF—primarily by improving skeletal
muscle function—but possibly by reducing inflammation as
well.23 Whether exercise can prevent HF in COPD patients
needs evaluation.
Some of the traits mentioned above as covariates and potential
intermediaries may be associated with HF directly or indirectly
through their association with CHD. For instance, low FVC is asso-
ciated with subclinical atherosclerosis24 and incident ischaemic
heart disease.5 Empirically, excluding those with prevalent CHD
Figure 3 Multivariable adjusted cumulative-events estimates
for incident heart failure by quartiles of forced expiratory
volume in 1 s, i.e. Q1–Q4. Adjusted for age, gender, race,
height, height × height, prevalent chronic heart disease, diabetes,
hypertension, cigarette smoking status, cigarette-years of
smoking, LDL-cholesterol, HDL-cholesterol, and body mass
index. The curves are statistically not similar, using log rank test
(P , 0.001). Data are from the Atherosclerosis Risk in Commu-
nities (ARIC) study baseline examination (1987–89) in a sub-
sample without prevalent HF and not missing information on
important covariates, followed up to 31 December 2004.
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at baseline did not visibly change the results (Supplementary ma-
terial online, Table S1).
Other potential mechanisms
An increase in pulmonary vascular resistance and pulmonary artery
pressure, and lower pulmonary vessel endothelial function and
endothelial proliferation in pulmonary vasculature is seen with al-
veolar hypoxia and in individuals with even mild/moderate
COPD.22,25 It seems reasonable to think that such changes may
manifest in early right ventricular structural26 and functional abnor-
malities that could ultimately lead to a deterioration of left ven-
tricular function and clinical HF due to interventricular
dependence.27 Further, animal studies show increased right-sided
heart injury with increased end-expiratory volume as seen in
acute exacerbation of COPD.28 However, this has been a debat-
able issue as many studies have not seen differences in right ven-
tricular structure or function with mild COPD.29 Several other
mechanisms such as systemic inflammation, autonomic dysfunction,
oxidative stress, and chronic muscle wasting have been implicated
to result in new-onset HF in individuals with COPD.
Strengths/limitations/future research
The strengths of our findings include their prospective and
population-based nature, their internal consistency—including
among non-smokers—the sizeable magnitude of HR estimates
even after multivariable adjustment, and the imperviousness of
the results to various sensitivity analyses. Several limitations of
this study should also be mentioned. The most important among
them is the lack of validation and detailed characterization of the
HF events. Further, respiratory symptoms and diagnoses were self-
reported and not validated. Perhaps less worrisome, smoking
status was self-reported and not validated with biomarkers, thus
some residual confounding due to smoking could not be ruled
out, and neither post-bronchodilator lung function nor total lung
volume were measured. Due to use of pre-bronchodilator re-
sponse, the specificity of diagnosis of COPD should be lower,
and this, if anything, will dilute the effect estimate towards null.
This is also clear as the estimate for moderate COPD is higher
than for mild COPD. We also examined the potential confounding
bias introduced by heart rate, and the use of beta-blockers, adren-
ergic medication use, steroid intake, and xanthine use, but did not
see evidence of appreciable confounding (data not shown).
Misclassification of hospitalized COPD exacerbations as HF is
conceivable given the many overlapping signs and symptoms,30
and that the HF events in this study were not validated by chart
review. An ICD code 428.x has a positive predictive value of
94.3% when compared with Framingham criteria,31 and 83.0%
compared with a physician diagnosis and pulmonary oedema on
chest X-ray.32 To evaluate whether our findings may be a result
of misclassification of incident HF, sensitivity analyses were
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Table 3 Hazard ratios of heart failure for airway obstruction, and self-reported diagnosis of respiratory disease
(N 5 13 130)
Gender Model 1a Model 2b
HR (95% CI) HR (95% CI)
Men COPD vs. no COPD by spirometry 1.61 (1.36–1.91) 1.44 (1.20–1.74)
Mild COPD vs. no COPD by spirometry 0.90 (0.69–1.18) 0.98 (0.74–1.29)
Moderate/severe COPD vs. no COPD by spirometry 2.30 (1.90–2.77) 1.83 (1.49–2.26)
Chronic bronchitisc 2.07 (1.60–2.69) 1.42 (1.03–1.98)
Self-reported diagnosis of bronchitis 1.65 (1.20–2.27) 1.44 (1.04–2.00)
Self-reported diagnosis of emphysema 2.22 (1.51–3.25) 1.85 (1.23–2.77)
Self-reported diagnosis of COPDd 1.70 (1.30–2.20) 1.44 (1.08–1.91)
Self-reported diagnosis of asthma 1.06 (0.74–1.51) 1.15 (0.80–1.64)
Women COPD vs. no COPD by spirometry 1.40 (1.15–1.71) 1.40 (1.13–1.72)
Mild COPD vs. no COPD by spirometry 0.90 (0.67–1.20) 1.07 (0.79–1.45)
Moderate/severe COPD vs. no COPD by spirometry 2.09 (1.65–2.65) 1.73 (1.34–2.22)
Chronic bronchitisc 2.11 (1.54–2.99) 1.74 (1.34–2.19)
Self-reported diagnosis of bronchitis 2.27 (1.83–2.82) 1.84 (1.84–5.28)
Self-reported diagnosis of emphysema 4.41 (2.72–7.16) 3.12 (2.11–5.93)
Self-reported diagnosis of COPDd 2.40 (1.94–2.96) 1.84 (1.47–2.31)
Self-reported diagnosis of asthma 1.60 (1.17–2.17) 1.56 (1.14–2.13)
Data are from the Atherosclerosis Risk in Communities (ARIC) study baseline examination (1987–89) in a subsample without prevalent HF and not missing information on
important covariates, followed up to 31 December 2004.
Using spirometry, any COPD was defined as FEV1/FVC ,70%, mild COPD was defined as FEV1/FVC ,70% and FEV ≥80% (predicted), moderate/severe COPD was defined as
FEV1/FVC ,70% and FEV1 ,80% (predicted), and no COPD as FEV1/FVC ≥70%.
CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HR, hazard ratio.
aModel 1 is adjusted for age and race.
bModel 2 is adjusted for age, smoking status, cigarette-years of smoking, hypertension, diabetes, LDL-cholesterol, HDL-cholesterol, and body mass index.
cChronic bronchitis was defined as productive cough for at least 3 months in two contiguous years.
dSelf-reported diagnosis of COPD is the presence of self-reported diagnosis of either bronchitis or emphysema.
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conducted as stated in the Methods. The estimated associations
did not change appreciably following the exclusion of COPD at
baseline, or by censoring those with concurrent COPD and HF
(Supplementary material online, Table S1). Lastly, a decreased
lung function may contribute to early exacerbation of asymptom-
atic ventricular dysfunction and possibly to lead-time bias. Given
the strength of the estimates observed and the almost constant
HR estimates over time, these biases, if present, are unlikely to
have an effect that would alter the inferences presented here.
Studies are needed that can address the associations reported
here with further characterization of HF into systolic and diastolic
phenotypes. Whether improvement (or a slower decline) in lung
function with smoking cessation,33 increased physical activity,34
or other novel interventions is related to future risk of HF similarly
need attention. In a population-based study, computed tomog-
raphy (CT) scan-defined emphysema and spirometry-defined
airflow obstruction were linearly associated with impaired ven-
tricular filling and reduced cardiac output, but not with ejection
fraction.8 A recently reported huge burden on unrecognized HF
in patients with COPD35 further suggests that more attention to
HF in individuals with COPD is warranted. An enhanced under-
standing of the pathophysiological changes in heart structure and
function in the context of COPD would be similarly important.
In conclusion, in this large population-based closed cohort study
with long-term follow-up, we observe that low FEV1, self-reported
COPD, and airway obstruction are associated with incident HF.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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